Have any questions? 706-721-6582 or cts@augusta.edu
- FURI: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (SCY-078-301)
Clinical Trial
FURI: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (SCY-078-301)
This study will try to see how safe and effective the new anti-fungal drug called SCY-078 is to treat adults whose fungal infection does not respond to standard anti-fungal treatment, or who are unable to tolerate such standard treatment.
Eligibility Criteria
- INCLUSION: 1. Adult age 18 years or older with a fungal infection that does not respond well to standard treatment, or a patient who cannot tolerate the treatment. 2. Subject can take the medication by mouth, or through a nasogastric (NG) or feeding tube. EXCLUSION: 1. The fungal infection affects certain areas of the body not allowed by the study. 2. The subject has lab values out of the ranges allowed by the study, or has other medications not allowed.
RESEARCH. INNOVATION. DISCOVERY.